Compare Axogen Inc (AXGN) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Axogen Inc trades at $38.76 (market cap $2.06B), while Marsh & McLennan Companies, Inc. trades at $177.68 (market cap $85.78B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 41.6× Axogen Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.22% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | MRSH | |
|---|---|---|
Market Cap | $2.06B | $85.78B |
Sector | Technology | Financials |
52-Week High | $46.19 | $212.28 |
52-Week Low | $11.28 | $157.32 |
Enterprise Value | $1.98B | $106.62B |
Dividend Yield | — | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
Marsh (MRSH) trades at $181.53, up 1.81% with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.29 exceeding expectations. Revenue grew to $26.98B in 2025 with a 14.26% net margin, while recent dividend increases and strategic acquisitions highlight management's confidence in cash flow generation.
The stock presents a balanced outlook with 33% analyst buy ratings and a $203.67 consensus target offering 12% upside. However, elevated valuation ratios and bearish oscillators suggest near-term consolidation risk. Key catalysts include Q2 2026 earnings and sustained organic growth amid easing insurance pricing headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
